Inmolecule Nanotech SA
EEURONEXT:MLINA3.98
EUR
0.00
(0.00%)
ISIN
ES0105908000
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
EUR
•
in mil. unless spec.Working Capital
EUR
•
in mil. unless spec.Growth Rates
EUR
•
in mil. unless spec.Quarterly Revenue
EUR
•
in mil. unless spec.Quarterly Earnings Per Share
EUR
•
in mil. unless spec.Quarterly Dividends Per Share
EUR
•
in mil. unless spec.Company Description
- CEO
- Sergio Manuel León Gutierrez
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Madrid Spain
- IPO Date
- Aug 18, 2025
- Website
- inmolecule.com
- Similar Companies
- Business
- Inmolecule Nanotech, S.A. is a biotechnology company that develops, manufactures, and commercializes advanced nanotechnology-based antimicrobial, hygiene, healthcare, and bio-protection solutions. The company utilizes a proprietary, patented nanophytochemistry technology platform that engineers active ingredient nanoparticles derived from plant extracts to neutralize bacteria, viruses, fungi, mycobacteria, and microbial spores. Its diversified product portfolio spans several commercial segments, including personal care and cosmetic formulations, such as antiseptic treatments, dermatological solutions, and daily hygiene products; institutional and household care items, comprising non-toxic surface disinfectants and sanitizing agents; agricultural bio-protection and crop health solutions, consisting of botanical pathogen control agents and bio-inputs designed to protect harvests sustainably; aquaculture and veterinary products, including biosecurity treatments and water sanitization additives for livestock and fish farming; and health and wellness supplements, featuring nanoparticle-formulated dietary products such as vitamin C and zinc preparations. Inmolecule Nanotech serves institutional, agricultural, industrial, and consumer markets across Europe, North America, and Africa. Founded in 1999, the company is headquartered in Madrid, Spain. In August 2025, Inmolecule Nanotech completed a significant corporate milestone by listing its shares on the Euronext Access Paris exchange under the ticker symbol MLINA via a direct listing at a reference price of 3.82 euros per share. Following its public debut, the company expanded its international commercialization initiatives, strengthened industrial and distribution alliances across European and American markets, and accelerated the deployment of its bio-based nanotechnology platform into global agricultural, healthcare, and consumer goods sectors.